Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 491.82M |
| Revenue (ttm) | 67.49M |
| Net Income (ttm) | -257.56M |
| Shares Out | 66.55M |
| EPS (ttm) | -6.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,505,498 |
| Open | 7.04 |
| Previous Close | 7.13 |
| Day's Range | 7.01 - 7.49 |
| 52-Week Range | 3.28 - 14.28 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 10.91 (+47.6%) |
| Earnings Date | Aug 2, 2022 |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK... [Read more...]
Financial Performance
In 2021, ESPR's revenue was $78.45 million, a decrease of -65.52% compared to the previous year's $227.55 million. Losses were -$269.11 million, 87.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is 10.91, which is an increase of 47.63% from the latest price.
News
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on August 2, 2022, the Compensation Committee of Esperion's Board of Directors granted 13 new employees ...
Esperion (ESPR) Q2 Earnings and Revenues Miss Estimates
Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Misses Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -10.53% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 –
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB represent ...
Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
ANN ARBOR, Mich., July 12, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on Tuesday...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Esperion Therapeutics, Inc. for Potential Breaches of Fid...
NEW YORK , June 15, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim i...
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not ...
– Less than 1 in 10 were on any non-statin lipid lowering therapy –
Esperion Therapeutics (ESPR) Down 15.1% Since Last Earnings Report: Can It Rebound?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
ANN ARBOR, Mich., June 01, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of J. Martin Carroll as Chairperson of Esperion's Board of Directors. Mr. Carroll will serve a...
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter.
Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcomin...
Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs
Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins.
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 3.12% and 21.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
– Unprecedented CLEAR Outcomes Study Approaching 95% MACE Accumulation–
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America Sec...
Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
ANN ARBOR, Mich., April 28, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Stephen Rocamboli as a Class I director, with a term expiring at the 2023 annual meeting o...
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Should You Buy?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report First Quarter 2022 Financial Results May 3, 2022
ANN ARBOR, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on Tuesday...
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Analysis of pooled Phase 3 data demonstrated 26.5% reduction vs. placebo in LDL-C from bempedoic acid monotherapy and 39.2% reduction vs. placebo in LDL-C from bempedoic acid and ezetimibe fixed-dose co...
Esperion's (ESPR) Drug Sales and Cost-Cutting Drive Stock YTD
Esperion's (ESPR) stock rallies so far this year on higher product sales in the fourth quarter of 2021. Cost-saving initiatives to boost margins in 2022 are another key drivers.
Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology's 71st Ann...
New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hy...
Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21st Annual ...
Why Is Esperion Therapeutics (ESPR) Up 29.1% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?